Protalix BioTherapeutics Profit Margin

The latest profit margin for PLX is 23.5% as of June 2026. That compares with 10.13% in the prior-year period — up 132.0% year over year. That is above the Healthcare sector average of 13.89%. Investors often review this figure alongside Protalix BioTherapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, PLX's profit margin moved from 10.13% to 23.5% — a 132.0% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Protalix BioTherapeutics's valuation or profitability profile.

Against Healthcare companies, PLX currently prints 23.5% for profit margin, while the sector average sits near 13.89%. That is roughly 69.2% above the sector mean. Large gaps often invite a closer look at Protalix BioTherapeutics's growth, margins, and balance sheet.

Profit Margin shows how effectively Protalix BioTherapeutics converts resources into returns. At 23.5%, PLX may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with 10.13% in the prior-year period — up 132.0% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting PLX's profit margin (23.5%), review year-over-year change from 10.13%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.